Does TALIMOGENE LAHERPAREPVEC Cause Metastatic malignant melanoma? 109 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 109 reports of Metastatic malignant melanoma have been filed in association with TALIMOGENE LAHERPAREPVEC (Imlygic). This represents 7.4% of all adverse event reports for TALIMOGENE LAHERPAREPVEC.
109
Reports of Metastatic malignant melanoma with TALIMOGENE LAHERPAREPVEC
7.4%
of all TALIMOGENE LAHERPAREPVEC reports
42
Deaths
10
Hospitalizations
How Dangerous Is Metastatic malignant melanoma From TALIMOGENE LAHERPAREPVEC?
Of the 109 reports, 42 (38.5%) resulted in death, 10 (9.2%) required hospitalization, and 3 (2.8%) were considered life-threatening.
Is Metastatic malignant melanoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALIMOGENE LAHERPAREPVEC. However, 109 reports have been filed with the FAERS database.
What Other Side Effects Does TALIMOGENE LAHERPAREPVEC Cause?
Off label use (196)
Pyrexia (135)
Product storage error (133)
Circumstance or information capable of leading to medication error (89)
Death (82)
Influenza like illness (82)
Fatigue (70)
Chills (68)
Malignant melanoma (64)
Therapy partial responder (56)
What Other Drugs Cause Metastatic malignant melanoma?
DABRAFENIB (449)
TRAMETINIB DIMETHYL SULFOXIDE (267)
TRAMETINIB (173)
SILDENAFIL (116)
NIVOLUMAB (87)
PREDNISONE (77)
PEMBROLIZUMAB (74)
TADALAFIL (71)
IPILIMUMAB (69)
INFLIXIMAB (61)
Which TALIMOGENE LAHERPAREPVEC Alternatives Have Lower Metastatic malignant melanoma Risk?
TALIMOGENE LAHERPAREPVEC vs TALQUETAMAB
TALIMOGENE LAHERPAREPVEC vs TALQUETAMAB-TGVS
TALIMOGENE LAHERPAREPVEC vs TAMIFLU
TALIMOGENE LAHERPAREPVEC vs TAMOXIFEN
TALIMOGENE LAHERPAREPVEC vs TAMSULOSIN